Drug delivery composition
Inventors
Fujiwara, Takayuki • HIROOKA, Shunsuke • Miyagishima, Shin-ya • OMATSU, Tsutomu
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
There is provided a drug delivery composition containing an acid-resistant cell that encloses a drug in the cell. In addition, there is provided an acid-resistant cell in which a drug is enclosed in the cell, where the drug is localized in the sac-shaped membrane structure included in the acid-resistant.
Core Innovation
The invention relates to a drug delivery composition comprising an acid-resistant cell that encloses a drug. The acid-resistant cell is a haploid cell of algae belonging to the class Cyanidiophyceae, wherein cell rupture is caused at pH 7. By using an acid-resistant haploid algal cell that ruptures at intestinal or neutral pH, the composition protects an enclosed drug from gastric degradation associated with acidic conditions.
The enclosed drug is localized in a sac-shaped membrane structure included in the acid-resistant cell. The sac-shaped membrane structure includes exogenous liposomes, a cell membrane, and/or an organelle, with organelles selected from mitochondria, chloroplasts, endoplasmic reticulum, vacuoles, cell nucleus, peroxisomes, and Golgi apparatus. This localization is described as reducing cytosolic degradation of the enclosed drug.
The invention further describes a production concept using a fusion protein gene with a translocation signal or protein configured to localize the drug to a desired sac-shaped membrane structure. The described gene constructs include fusion constructs expressed in Cyanidiophyceae, including Cyanidioschyzon merolae strains expressing rabies GP and GFP fusion constructs. The document presents that rupture and degradation dependence and intracellular localization differ by conditions such as proteasome dependence and localization choice, and that detection and immune responses are observed in the small intestine after administration.
Claims Coverage
The independent claims identified are clm-00001, clm-00012, clm-00013, clm-00015, and clm-00017. Across these independent claims, the inventive features are centered on an acid-resistant haploid Cyanidiophyceae cell that encloses a drug or exogenous substance and ruptures at pH 7, with additional independent coverage including localization in a sac-shaped membrane structure and a fusion protein localization concept.
Acid-resistant haploid Cyanidiophyceae cell rupturing at pH 7 enclosing a drug
An acid-resistant cell that encloses a drug, wherein the acid-resistant cell causes cell rupture at pH 7 and is a haploid cell of algae belonging to the class Cyanidiophyceae.
Acid-resistant haploid Cyanidiophyceae cell rupturing at pH 7 enclosing a drug with sac-shaped membrane localization
An acid-resistant cell that encloses a drug, wherein the drug is localized in a sac-shaped membrane structure included in the acid-resistant cell, and wherein the acid-resistant cell causes cell rupture at pH 7 and is a haploid cell of algae belonging to the class Cyanidiophyceae.
Acid-resistant haploid Cyanidiophyceae cell rupturing at pH 7 as a drug carrier
A drug carrier comprising an acid-resistant cell, wherein the acid-resistant cell causes cell rupture at pH 7 and is a haploid cell of algae belonging to the class Cyanidiophyceae.
Acid-resistant haploid Cyanidiophyceae cell rupturing at pH 7 comprising an exogenous substance
An acid-resistant cell comprising an exogenous substance, wherein the acid-resistant cell causes cell rupture at pH 7 and is a haploid cell of algae belonging to the class Cyanidiophyceae.
Collectively, the independent claims require an acid-resistant haploid algal cell of Cyanidiophyceae that ruptures at pH 7 and encloses a drug or comprises an exogenous substance, with additional independent coverage including localization of the drug or exogenous substance in a sac-shaped membrane structure.
Stated Advantages
Protects an enclosed drug from gastric degradation.
Localizes the drug to reduce cytosolic degradation.
Enables detection and localization in the small intestine with minimal detection in the stomach.
Induces anti-GP protein antibody after oral administration via suspension or alginate-solidified feed administration.
Documented Applications
Oral delivery of an enclosed drug using an acid-resistant Cyanidiophyceae haploid algal cell for intestinal delivery, including detection of sfGFP in the small intestine and minimal detection in the stomach.
Intestinal immune activation, including induction of anti-GP antibodies after administration of suspension or alginate-solidified feed containing acid-resistant algal cells expressing rabies GP fusion constructs.
Use as a feed additive and as a pharmaceutical product, food, or drug capsule concept for oral delivery in the described manner.
Interested in licensing this patent?